Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Ascites

• Oral Branched-chain Amino Acid Supplementation for Decompensated Cirrhotic Patients
• Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites
• Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
• Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)™
• High Dose Albumin in Refractory Ascites
• Phase II/III of Recombinant Human Serum Albumin
• Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
• Empagliflozin in Patients With Cirrhosis and Ascites
• Allopurinol Versus Simvastatin to Prevent Complications of Liver Cirrhosis
• PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
• Single Dose Escalation of PHIN-214 in Child-Pugh A Liver Cirrhotics
• Empagliflozin as a Novel Therapy in Refractory Ascites
• HRS-AKI Treatment With TIPS in Patients With Cirrhosis
• A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
• Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
• Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
• Recombinant Human Serum Albumin in Healthy Subjects
• Efficacy and Safety of Midodrine in Refractory or Recurrent Ascites in Children With Cirrhosis.
• Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices
• Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
• Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
• Empagliflozin in Diuretic Refractory Ascites
• A Phase II Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites
• Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.
• Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites
• Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
• Phase Ib of Recombinant Human Albumin Injection
• Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.
• Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.
• Midodrine and Albumin in Patients With Refractory Ascites
• A Study of M701 (EpCAM and CD3) in Malignant Ascites
• A Study of OsrHSA in Adult Healthy Male and Female Volunteers
• Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
• The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
• Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites.
• Effect of Ascites Replacement Strategy on Time to 1st Flatus After LDLT
• A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
• Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites
• Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
• Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children
• S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
• A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
• A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
• A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
• Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites
• Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
• Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
• Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
• Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
• PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
• A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
• Metabolic Effects of Furosemide +HSS in Refractory Ascites
• Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma
• The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites
• The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites
• To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites
• Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT
• A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
• Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)
• Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
• AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
• Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
• Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
• Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
• Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites
• Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy
• Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects
• Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
• Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
• VSL#3 and Spontaneous Bacterial Peritonitis
• Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites
• Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
• The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS
• Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
• Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
• Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
• Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis
• Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
• Tolvaptan for Ascites in Cirrhotic Patients
• Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis
• Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
• Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
• Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia
• Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
• Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
• Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
• Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
• Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in Cirrhotics
• A Study of Bevacizumab to Prevent Malignant Ascites
• CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
• Trial of Sunitinib for Refractory Malignant Ascites
• Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients
• Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
• Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function
• Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
• Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
• Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
• Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
• Satavaptan Dose-Ranging Study in the Prevention of Ascites
• Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction
• AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
• Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
• Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
• Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
• Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
• Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
• Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
• The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction
• Prevention of Decompensation in Liver Cirrhosis
• Octreotide in Treating Patients With Cancer-Related Malignant Ascites
• Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites
• Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
• Treatment With Octreotide in Patients With Lymphangioleiomyomatosis